SPEX — Spexis AG Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Primary Endpoint
Brief: Polyphor AG Provides Update On Phase III Fortress Study Of Balixafortide In Patients With Advanced HER2 Negative Breast Cancer
Brief: Polyphor's Balixafortide Shows Efficacy In COVID-19 Preclinical Trials
Brief: Polyphor FY Total Loss At CHF 44.9 Million
Brief: Polyphor Receives Approval To Start First-In-Human Clinical Trial Of Inhaled Antibiotic Murepavadin
Swiss stocks - Factors to watch on December 22
Brief: Polyphor: DSMB Says Phase III Balixafortide Study To Go On Without Modifications
Brief: Polyphor Gets USD 2.3 Mln Award From Carb-X To Support Development Of New Class Of Antibiotics
Brief: Polyphor Receives Up To USD 3.3 Million To Develop Murepavadin
Brief: Polyphor Gets Carb-X Award Of Up To USD 18.44 Mln To Support Development Of New Antibiotic Program
Brief: Polyphor Closing Of Fosun Pharma Licensing Agreement For Balixafortide In China
Brief: Polyphor H1 Total Loss At CHF 27.8 Mln
Brief: Polyphor And Fosun Pharma Announce Licensing Agreement For Balixafortide In China
Brief: Polyphor Announces Second Positive Data Safety Monitoring
Brief: Polyphor Enters Into Equity-linked Financing Arrangement With French Co Iris
Brief: Polyphor Announces Acceptance Of Balixafortide Abstract At ASCO 2020 Virtual Scientific Program
Brief: Polyphor FY Total Loss At CHF 64.7 Mln
Brief: Polyphor: Data Safety Monitoring Board Recommends To Continue Phase III Fortress Study Without Modifications
Brief: Polyphor Announces Progress Of Phase III Immuno-Oncology Program With Balixafortide